|
Mesothelioma Chemotherapy Journal Articles
Cytoreductive
surgery and intraperitoneal chemotherapy for peritoneal mesothelioma.
Cisplatin
and vinorelbine first-line chemotherapy in non-resectable malignant
pleural mesothelioma
Active
symptom control with or without chemotherapy in the treatment of patients
with malignant pleural mesothelioma (MS01): a multicentre randomised
trial
Molecular
analysis of the effects of Piroxicam and Cisplatin on mesothelioma
cells growth and viability
A randomised trial in malignant mesothelioma of
early versus delayed chemotherapy in symptomatically stable patients:
the MED trial.
Malignant peritoneal mesothelioma. Our experienced
with triple combined therapy: cytoreduction, intraperitoneal perioperative
chemotherapy and hyperthermia
Prognostic indicators for patients undergoing cytoreductive
surgery and perioperative intraperitoneal chemotherapy for diffuse
malignant peritoneal mesothelioma.
Malignant
Mesothelioma Continues to Present a Difficult Therapeutic Target
- ASCO report
The diagnostic utility of D2-40 for malignant mesothelioma
versus pulmonary carcinoma with pleural involvement.
Positron emission tomography predicts survival
in malignant pleural mesothelioma.
Gene therapy for malignant mesothelioma: beyond
the infant years.
Multimodality approach in management of malignant
pleural mesothelioma.
Piroxicam
and intracavitary platinum-based chemotherapy for the treatment of
advanced mesothelioma in pets: preliminary observations
Physical and chemical stability of pemetrexed in
infusion solutions.
Statins revert doxorubicin resistance via nitric
oxide in malignant mesothelioma
Prognostic factors in mesothelioma
Thalidomide in patients with malignant pleural mesothelioma.
The value of ThinPrep and cytospin preparation in
pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Novel Complimentary Therapies Boost Role of Surgery
for Mesothelioma Cancer
Chemotherapy for malignant pleural mesothelioma:
past results and recent developments
Chemotherapy options and new advances in malignant
pleural mesothelioma.
Assessing quality of life during chemotherapy for
pleural mesothelioma
Do patients with weight loss have a worse outcome
when undergoing chemotherapy for lung cancers?
Pemetrexed in combination with cisplatin in the
treatment of chemonaive patients with malignant pleural mesothelioma
(MPM)
A phase I study of Foscan-mediated photodynamic
therapy and surgery in patients with mesothelioma
Pemetrexed alone or in combination with cisplatin
in the treatment of patients with peritoneal mesothelioma (PM)
Pemetrexed therapy for malignant pleural mesothelioma.
The evolving role of pemetrexed (Alimta) in lung
cancer
Overview of phase I/II pemetrexed studies.
Irinotecan for malignant mesothelioma
Raltitrexed–Oxaliplatin combination chemotherapy
is inactive as second-line treatment for malignant pleural mesothelioma
patients
Triplet chemotherapy with cisplatin, gemcitabine
and vinorelbine for malignant pleural mesothelioma.
Limited efficacy of imatinib mesylate in malignant
mesothelioma: A phase II trial
Randomized phase III trial of pemetrexed versus
docetaxel in patients with non-small-cell lung cancer previously treated
with chemotherapy.
Homocysteine and Methylmalonic Acid: Markers
to Predict and Avoid Toxicity from Pemetrexed Therapy
Interferon Alpha May Help Treat Malignant Pleural
Mesothelioma
Xenavex
Ribonucleases as a Novel Pro-Apoptotic Anticancer
Strategy
Effective therapy of human lymphoma xenografts
with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody
immunotoxin.
Trial of a single weekly intravenous dose of ranpirnase
in patients with unresectable malignant mesothelioma.
Effect of N-terminal and Met23 mutations on the
structure and dynamics of onconase.
A phase II study of intrapleural immuno-chemotherapy,
pleurectomy/decortication, radiotherapy, systemic chemotherapy and
long-term sub-cutaneous IL-2 in stage II–III malignant pleural mesothelioma
A retrospective analysis of malignant pleural mesothelioma
patients treated either with chemotherapy or best supportive care
between 1990 and 2005
Single-arm, open label study of pemetrexed plus
cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma:
Outcomes of an expanded access program
Activation of Caspases and Serine Proteases during
Apoptosis Induced by Onconase
Many experts say that germs have the ability to make the body adjust
and learn about the fighting back mechanism against tumors.
If you have mesothelioma,
we might be able to help you. Fill out this form.
This website is sponsored by Jonathan David* of The
David Law Firm. The David Law Firm is located in The Woodlands, Texas
(Greater Houston Area) and can be reached toll free at 1-800-998-9729
for more information on mesothelioma. Jonathan David is not a medical
doctor. The information on these pages is for the education of mesothelioma
patients and their families regarding potential medical and legal
options. Patients are advised to consult with a medical doctor.
* Licensed
by the Supreme Court of Texas.
|
